Solid Biosciences Inc.
Simbols: SLDB
NASDAQ
10.23
USDTirgus cena šodien
-2.2174
P/E koeficients
0.0499
PEG koeficients
386.25M
MRK Cap
- 0.00%
DIV ienesīgums
Solid Biosciences Inc. (SLDB) Finanšu pārskati
Bilance
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 612.23 | 123.6 | 213.7 | 207.8 | |||||||||
balance-sheet.row.short-term-investments | 232.96 | 49.6 | 58.3 | 88.6 | |||||||||
balance-sheet.row.net-receivables | 0 | 0 | 0 | 0.1 | |||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 6 | |||||||||
balance-sheet.row.other-current-assets | 14.25 | 6.1 | 5.9 | 8.7 | |||||||||
balance-sheet.row.total-current-assets | 636.16 | 129.7 | 219.6 | 222.6 | |||||||||
balance-sheet.row.property-plant-equipment-net | 139.54 | 33.2 | 38.6 | 7.6 | |||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.long-term-investments | 7.33 | 1.8 | 1.8 | 2.1 | |||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.other-non-current-assets | 0.94 | 0.2 | 0.2 | 0.1 | |||||||||
balance-sheet.row.total-non-current-assets | 147.82 | 35.2 | 40.6 | 9.8 | |||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.total-assets | 783.98 | 164.9 | 260.3 | 232.4 | |||||||||
balance-sheet.row.account-payables | 12.49 | 2 | 3.2 | 4.5 | |||||||||
balance-sheet.row.short-term-debt | 9.14 | 2.3 | 2.6 | 1.5 | |||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.long-term-debt-total | 99.13 | 23.9 | 26 | 0.6 | |||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||
balance-sheet.row.other-current-liab | 22.88 | 10.2 | 16.7 | 9.6 | |||||||||
balance-sheet.row.total-non-current-liabilities | 99.13 | 23.9 | 26.1 | 0.6 | |||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.capital-lease-obligations | 105.95 | 23.9 | 28.5 | 2.1 | |||||||||
balance-sheet.row.total-liab | 165.62 | 38.5 | 48.6 | 24.2 | |||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.common-stock | 0.08 | 0 | 0 | 0.1 | |||||||||
balance-sheet.row.retained-earnings | -2507.41 | -658.8 | -562.7 | -476.8 | |||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0.04 | 0 | -0.1 | 0 | |||||||||
balance-sheet.row.other-total-stockholders-equity | 3125.66 | 785.2 | 774.5 | 684.9 | |||||||||
balance-sheet.row.total-stockholders-equity | 618.36 | 126.5 | 211.7 | 208.2 | |||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 783.98 | 164.9 | 260.3 | 232.4 | |||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.total-equity | 618.36 | 126.5 | 211.7 | 208.2 | |||||||||
balance-sheet.row.total-liabilities-and-total-equity | 783.98 | - | - | - | |||||||||
Total Investments | 234.79 | 51.5 | 58.3 | 88.6 | |||||||||
balance-sheet.row.total-debt | 108.27 | 26.3 | 28.5 | 2.1 | |||||||||
balance-sheet.row.net-debt | -271 | -47.8 | -126.8 | -117.1 |
Naudas plūsmas pārskats
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -96.02 | -96 | -86 | -72.2 | |||||||||
cash-flows.row.depreciation-and-amortization | 2.96 | 2.6 | 2.4 | 3 | |||||||||
cash-flows.row.deferred-income-tax | -46.06 | -13.6 | 0 | 1.2 | |||||||||
cash-flows.row.stock-based-compensation | 7.63 | 7.6 | 7.5 | 13.4 | |||||||||
cash-flows.row.change-in-working-capital | -6.34 | -6.3 | -3.7 | -23 | |||||||||
cash-flows.row.account-receivables | 0 | 0 | 0.1 | -0.1 | |||||||||
cash-flows.row.inventory | 0 | 0 | 0 | -11.5 | |||||||||
cash-flows.row.account-payables | -0.76 | -0.8 | -5.2 | 1.2 | |||||||||
cash-flows.row.other-working-capital | -4.67 | -5.6 | 1.4 | -12.6 | |||||||||
cash-flows.row.other-non-cash-items | 43.65 | 11.5 | -18.3 | -0.1 | |||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -94.18 | 0 | 0 | 0 | |||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -1.51 | -1.5 | -3 | -1.3 | |||||||||
cash-flows.row.acquisitions-net | 26.56 | -9.7 | 31.5 | 89.8 | |||||||||
cash-flows.row.purchases-of-investments | -117.43 | -117.4 | -182.8 | -141.2 | |||||||||
cash-flows.row.sales-maturities-of-investments | 128.63 | 128.6 | 212.8 | 51.4 | |||||||||
cash-flows.row.other-investing-activites | 11.2 | 9.7 | 0.6 | -89.8 | |||||||||
cash-flows.row.net-cash-used-for-investing-activites | 9.69 | 9.7 | 59.2 | -91.1 | |||||||||
cash-flows.row.debt-repayment | 0 | 0 | -0.1 | 0 | |||||||||
cash-flows.row.common-stock-issued | 5.51 | 3 | 72.6 | 134.9 | |||||||||
cash-flows.row.common-stock-repurchased | 0.16 | 0 | 0 | 0 | |||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.other-financing-activites | -5.16 | 0.1 | 2.3 | 0.1 | |||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 5.74 | 3.1 | 74.8 | 135 | |||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 76.19 | 0 | 0 | 0 | |||||||||
cash-flows.row.net-change-in-cash | -81.37 | -81.4 | 36 | -33.9 | |||||||||
cash-flows.row.cash-at-end-of-period | 384.77 | 74 | 157.2 | 121.2 | |||||||||
cash-flows.row.cash-at-beginning-of-period | 466.14 | 155.4 | 121.2 | 155.1 | |||||||||
cash-flows.row.operating-cash-flow | -94.18 | -94.2 | -98 | -77.8 | |||||||||
cash-flows.row.capital-expenditure | -1.51 | -1.5 | -3 | -1.3 | |||||||||
cash-flows.row.free-cash-flow | -95.69 | -95.7 | -101 | -79 |
Peļņas vai zaudējumu aprēķina rinda
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 0 | 8.1 | 13.6 | |||||||||
income-statement-row.row.cost-of-revenue | 2.96 | 2.6 | 2.4 | 58.7 | |||||||||
income-statement-row.row.gross-profit | -2.96 | -2.6 | 5.7 | -45.1 | |||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||
income-statement-row.row.research-development | 76.56 | - | - | - | |||||||||
income-statement-row.row.selling-general-administrative | 27.75 | - | - | - | |||||||||
income-statement-row.row.selling-and-marketing-expenses | -0.59 | - | - | - | |||||||||
income-statement-row.row.other-expenses | 1.09 | 0 | -0.4 | 0 | |||||||||
income-statement-row.row.operating-expenses | 103.73 | 101.7 | 107.4 | 85.9 | |||||||||
income-statement-row.row.cost-and-expenses | 104.31 | 104.3 | 107.4 | 85.9 | |||||||||
income-statement-row.row.interest-income | 7.14 | 7.1 | 2.6 | 0.1 | |||||||||
income-statement-row.row.interest-expense | -1.96 | 0 | -20.5 | 0 | |||||||||
income-statement-row.row.selling-and-marketing-expenses | -0.59 | - | - | - | |||||||||
income-statement-row.row.total-other-income-expensenet | 6.35 | 8.3 | 20.5 | 0.1 | |||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||
income-statement-row.row.other-operating-expenses | 1.09 | 0 | -0.4 | 0 | |||||||||
income-statement-row.row.total-operating-expenses | 6.35 | 8.3 | 20.5 | 0.1 | |||||||||
income-statement-row.row.interest-expense | -1.96 | 0 | -20.5 | 0 | |||||||||
income-statement-row.row.depreciation-and-amortization | 2.96 | 2.6 | -1.5 | 3 | |||||||||
income-statement-row.row.ebitda-caps | -102.01 | - | - | - | |||||||||
income-statement-row.row.operating-income | -104.25 | -104.3 | -106.5 | -72.3 | |||||||||
income-statement-row.row.income-before-tax | -96.02 | -96 | -86 | -72.2 | |||||||||
income-statement-row.row.income-tax-expense | -4.56 | 0 | -20.5 | -0.1 | |||||||||
income-statement-row.row.net-income | -94.06 | -96 | -65.5 | -72.1 |
Biežāk uzdotie jautājumi
Kas ir Solid Biosciences Inc. (SLDB) kopējie aktīvi?
Solid Biosciences Inc. (SLDB) kopējie aktīvi ir 164939000.000.
Kādi ir uzņēmuma gada ieņēmumi?
Gada ieņēmumi ir N/A.
Kāda ir uzņēmuma peļņas norma?
Uzņēmuma peļņas norma ir 0.000.
Kāda ir uzņēmuma brīvā naudas plūsma?
Brīvā naudas plūsma ir -4.694.
Kāda ir uzņēmuma neto peļņas norma?
Neto peļņas norma ir 0.000.
Kādi ir uzņēmuma kopējie ieņēmumi?
Kopējie ieņēmumi ir 0.000.
Kāda ir Solid Biosciences Inc. (SLDB) tīrā peļņa (tīrie ienākumi)?
Tīrā peļņa (tīrie ienākumi) ir -96015000.000.
Kāds ir uzņēmuma kopējais parāds?
Kopējais parāds ir 26265000.000.
Kāds ir pamatdarbības izdevumu skaits?
Darbības izdevumi ir 101734000.000.
Kāds ir uzņēmuma skaidrās naudas rādītājs?
Uzņēmuma nauda ir 74015000.000.